Caroline M Behler, MD
Hematology/Oncology · San Francisco
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 9
- 1 carrier
- Offices
- 6
- Since medical school
- 25 years
- University of Washington School of Medicine, 2001
Offices
6 locations · Sutter Bay Medical Foundation · Pacific Hematology Oncology Assoc.
Looking this up.
Hospitals listed: California Pacific Medical Center - Mission Bernal · California Pacific Medical Center- Van Ness Campus · California Pacific Medical Ctr-Davies Campus Hosp · Novato Community Hospital · UCSF Medical Center. That is not proof they admit you there this week.
Plans that list them
9 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Behler’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A82830 · Current
Licensed to practise in California · since 2003 · expires 2028-08-31 · University of Washington School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
5 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- California Pacific Medical Center - Mission BernalSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Church · Has an emergency departmentPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 3 of 5 · 76% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.322, Oct 2024 – Sep 2025
- California Pacific Medical Center- Van Ness CampusSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 78% would definitely recommend itOverall rating: 3 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.224, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.325, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.373, Oct 2024 – Sep 2025
- California Pacific Medical Ctr-Davies Campus HospSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Other · No emergency departmentPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 3 of 5 · 74% would definitely recommend itOverall rating: 3 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.187, Oct 2024 – Sep 2025
- Novato Community HospitalNovato, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 84% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0, Oct 2024 – Sep 2025
- UCSF Medical CenterSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of University of California Health, which runs 12 hospitalsHome of UCSF Helen Diller Family Comprehensive Cancer Center, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 81% would definitely recommend itOverall rating: 4 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 4.9 (3.79 to 6.02) · 7,590 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 12.8 (11.3 to 14.4) · 2,019 cases, Jan 2024 – Dec 2024Better than the national rate — Death rate among surgical inpatients with serious treatable complications: 139.4 (110.22 to 168.58) · 452 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.622, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.626, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.491, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.8 (0.7 to 1) · 2,336 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for California Pacific Medical Center - Mission Bernal
Behind the star rating — Deaths: 0 better, 5 the same, 0 worse of 5 measures. Safety: 1 better, 6 the same, 0 worse of 7 measures. Readmissions: 0 better, 3 the same, 3 worse of 6 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.322 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.24 (0.19 to 2.28) · 336 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.87 (0.47 to 1.27) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 163.19 (101.27 to 225.11) · 28 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 8.5 · 44 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.6 · 155 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13.4 · 177 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 11.6 · 32 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.2 · 1,281 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.19 (0 to 0.42) · 2,912 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.24 (0.04 to 0.45) · 2,681 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.07 (1.81 to 6.33) · 787 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.61 (0 to 3.31) · 425 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.46 (0.79 to 4.12) · 755 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.36 (0 to 16.38) · 431 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.47 (1.38 to 9.55) · 401 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.7 (0.2 to 3.2) · 105 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.27 (0 to 1.16) · 2,291 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 2.4 · 369 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.602 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.618 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22 · 242 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 20.9 · 197 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 39.6 · 203 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.1 · 292 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 4.9 · 353 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.9 · 74 cases | None | Jul 2023 – Jun 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.4) · 110 cases | No different | Jan 2024 – Dec 2024 |
What patients said (406 patients answered, 18% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 4 |
| Room was "always" clean | 76% |
| Nurses "always" communicated well | 78% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 60% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 85% |
| Doctors "always" explained things so they could understand | 78% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 74% |
| Staff "always" explained new medications | 74% |
| Nurses "always" explained things so they could understand | 76% |
| Nurses "always" listened carefully | 75% |
| Nurses "always" treated them with courtesy and respect | 83% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 76% |
| Staff "always" explained possible side effects | 47% |
| Yes, staff "did" give patients information about possible symptoms | 87% |
See every measure and the patient survey for California Pacific Medical Center- Van Ness Campus
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 1 better, 6 the same, 0 worse of 7 measures. Readmissions: 0 better, 8 the same, 2 worse of 10 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.224 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.325 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.373 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.14 (0.3 to 1.97) · 2,271 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.05 (0.81 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 192.86 (151.51 to 234.22) · 140 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.6 · 55 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 10.3 · 60 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.5 · 143 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.8 · 356 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.3 · 259 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 173 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.1 · 2,316 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.31 (0.12 to 0.49) · 6,430 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.09 to 0.47) · 7,168 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.3 (1.5 to 5.09) · 2,196 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2.47 (1.21 to 3.74) · 925 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.63 (1.37 to 3.88) · 1,954 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 10.13 (6.06 to 14.2) · 1,112 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.26 (4.67 to 9.85) · 1,084 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.67 (0.31 to 3.03) · 832 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.33 (0 to 0.85) · 5,406 cases | No different | Jul 2022 – Jun 2024 |
| MRSA BacteremiaInfections | 0.443 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.717 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.3 · 200 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.3 · 449 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 18.2 · 187 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 8.7 · 418 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 7.1 · 260 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 19.2 · 293 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (3.6 to 7.6) · 157 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.2 (7.7 to 13.5) · 157 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission for CABGUnplanned return visits | 11 · 33 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.2 · 66 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.5 (9.4 to 16.7) · 551 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.3) · 219 cases | No different | Jan 2024 – Dec 2024 |
What patients said (478 patients answered, 20% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 74% |
| Doctors "always" communicated well | 77% |
| Staff "always" explained | 59% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 75% |
| Doctors "always" treated them with courtesy and respect | 85% |
| Patients who gave a rating of "9" or "10" (high) | 75% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 70% |
| Nurses "always" listened carefully | 71% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 78% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
See every measure and the patient survey for California Pacific Medical Ctr-Davies Campus Hosp
Behind the star rating — Deaths: 0 better, 4 the same, 0 worse of 4 measures. Safety: 1 better, 5 the same, 0 worse of 6 measures. Readmissions: 0 better, 4 the same, 1 worse of 5 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.187 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.02 (0 to 2.09) · 232 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.98 (0.56 to 1.4) | No different | Jul 2022 – Jun 2024 |
| Death rate for heart failure patientsComplications and deaths | 10 · 72 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.1 · 106 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.4 · 257 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.8 · 721 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.26 (0.03 to 0.49) · 2,031 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.25 (0.04 to 0.45) · 2,032 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.35 (0.94 to 5.76) · 419 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.41 (0 to 3) · 211 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.84 (1.24 to 4.44) · 414 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 11.95 (2.91 to 20.98) · 218 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.61 (1.47 to 9.75) · 198 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.74 (0.22 to 3.26) · 52 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.32 (0 to 1.28) · 1,461 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.6 · 58 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.756 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.1 · 91 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 65.3 · 84 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -26.6 · 115 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.4 · 142 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.5 · 55 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 25 cases | None | Jul 2023 – Jun 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.3) · 312 cases | No different | Jan 2024 – Dec 2024 |
What patients said (602 patients answered, 22% of those asked)
| Cleanliness | 4 |
| Nurse communication | 2 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 73% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 59% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 73% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 85% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 68% |
| Nurses "always" listened carefully | 71% |
| Nurses "always" treated them with courtesy and respect | 81% |
| "Always" quiet at night | 46% |
| "YES", patients would definitely recommend the hospital | 74% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 85% |
See every measure and the patient survey for Novato Community Hospital
Behind the star rating — Deaths: 0 better, 5 the same, 0 worse of 5 measures. Safety: 0 better, 3 the same, 0 worse of 3 measures. Readmissions: 0 better, 7 the same, 0 worse of 7 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1 (0 to 2.06) · 213 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.85 (0.4 to 1.3) | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 8.2 · 25 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10 · 111 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 16.1 · 140 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 11.3 · 42 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.8 · 627 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.2 (0 to 0.43) · 1,872 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.25 (0.04 to 0.46) · 1,796 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.92 (0.5 to 5.33) · 505 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.64 (0 to 3.36) · 317 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.2 (0.51 to 3.88) · 495 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.93 (0 to 17.29) · 323 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.88 (0.69 to 9.07) · 311 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.75 (0.22 to 3.27) · 96 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.41 (0 to 1.49) · 1,320 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.2 · 143 cases | None | Apr 2023 – Mar 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.6 · 108 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -31.9 · 121 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 1.1 · 150 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.6 · 143 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.4 · 118 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 27 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.5 (9.5 to 16.5) · 930 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.3) · 184 cases | No different | Jan 2024 – Dec 2024 |
What patients said (334 patients answered, 30% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 78% |
| Nurses "always" communicated well | 81% |
| Doctors "always" communicated well | 83% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 78% |
| Doctors "always" listened carefully | 84% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 82% |
| Staff "always" explained new medications | 77% |
| Nurses "always" explained things so they could understand | 76% |
| Nurses "always" listened carefully | 82% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 54% |
| "YES", patients would definitely recommend the hospital | 84% |
| Staff "always" explained possible side effects | 49% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for UCSF Medical Center
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 3 better, 5 the same, 3 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.9 (3.79 to 6.02) · 7,590 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.8 (11.3 to 14.4) · 2,019 cases | Worse | Jan 2024 – Dec 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 139.4 (110.22 to 168.58) · 452 cases | Better | Jul 2022 – Jun 2024 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.622 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.626 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.491 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.7 to 1) · 2,336 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.24 (0.58 to 1.9) · 4,689 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.05 (0.89 to 1.2) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.9 · 89 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.5 · 85 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.1 · 132 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.6 · 454 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 618 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 380 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.7 · 5,000 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.22 (0.06 to 0.38) · 15,965 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.2 (0.05 to 0.35) · 17,859 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.85 (0 to 1.83) · 4,184 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2 (1.1 to 2.9) · 6,516 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.35 (4.49 to 10.21) · 3,989 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5 (3.22 to 6.77) · 4,087 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.95 (0.74 to 3.15) · 2,034 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.95 (0.63 to 1.28) · 15,431 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 399 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.899 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.689 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.224 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16 · 156 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20 · 564 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 60.3 · 160 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -9.7 · 550 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 44.1 · 660 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.8 · 667 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.7 (4.8 to 6.7) · 2,019 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6 · 421 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.5 · 53 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20 · 107 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.9 (11.3 to 17.1) · 3,247 cases | No different | Jan 2022 – Dec 2024 |
What patients said (3,181 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 71% |
| Nurses "always" communicated well | 80% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 78% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 50% |
| "YES", patients would definitely recommend the hospital | 81% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$1,927,883
Medicare paid this office $1,927,883 for 586 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Injection, daratumumab, 10 mg and hyaluronidase-fihj | 11 | $315,741 | None |
| Injection, pembrolizumab, 1 mg | 14 | $248,759 | None |
| Injection, denosumab, 1 mg | 26 | $130,599 | None |
| Return visit (30+ min) | 406 | $103,205 | $113 |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 27 | $42,981 | None |
See all 36 services
| Injection, daratumumab, 10 mg and hyaluronidase-fihj | 11 | $315,741 | None |
| Injection, pembrolizumab, 1 mg | 14 | $248,759 | None |
| Injection, denosumab, 1 mg | 26 | $130,599 | None |
| Return visit (30+ min) | 406 | $103,205 | $113 |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 27 | $42,981 | None |
| Administration of chemotherapy into vein, 1 hour or less | 76 | $36,885 | $138 |
| Long return visit (40+ min) | 117 | $32,771 | $166 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 21 | $11,452 | $74 |
| New patient visit (45+ min) | 49 | $7,169 | $146 |
| Administration of additional new drug or substance into vein, 1 hour or less | 31 | $6,033 | $68 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 15 | $5,514 | None |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 194 | $5,388 | $8 |
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 20 | $5,237 | $0 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 28 | $4,759 | $69 |
| Administration of prolonged chemotherapy into vein | 12 | $4,547 | $138 |
| Injection of drug or substance under skin or into muscle | 82 | $3,753 | $14 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 32 | $3,687 | $115 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 16 | $3,399 | $65 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 35 | $3,216 | $29 |
| New patient visit (60+ min) | 13 | $2,490 | $192 |
| Administration of chemotherapy into vein, each additional hour | 18 | $2,432 | $28 |
| Telephone medical discussion with physician, 21-30 minutes | 23 | $2,357 | $87 |
| Injection of additional new drug or substance into vein | 58 | $2,308 | $16 |
| Injection of drug or substance into vein | 33 | $1,816 | $37 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 19 | $1,703 | $36 |
| Injection, leucovorin calcium, per 50 mg | 12 | $1,434 | None |
| Short return visit (20+ min) | 16 | $1,218 | $76 |
| Telephone medical discussion with physician, 11-20 minutes | 13 | $1,212 | $81 |
| Injection, palonosetron hcl, 25 mcg | 44 | $867 | None |
| Infusion into a vein for hydration, 31-60 minutes | 15 | $819 | $34 |
| Application of on-body injector for under skin injection | 17 | $632 | $19 |
| Injection, fluorouracil, 500 mg | 12 | $611 | None |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 11 | $523 | $20 |
| Injection, dexamethasone sodium phosphate, 1 mg | 48 | $128 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 22 | $28 | None |
| Unclassified drugs | 13 | $21 | None |
Procedures year by year
| Procedure | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Biopsy of bone marrow | 12 | 13 | 18 | 16 | – | – |
| Aspiration of bone marrow sample for diagnosis | 12 | 13 | 18 | 16 | – | – |
| Biopsy and aspiration of bone marrow sample for diagnosis | – | – | – | – | 13 | – |
Times billed to Original Medicare each year. A blank year means fewer than 11 people had it, or none: Medicare does not publish smaller counts. Medicare Advantage patients are not included.
Who their Medicare patients are
586 Original Medicare patients in 2024. Average age 77 · Under 65 2% · 85 and older 20% · Women 57% · Also on Medicaid 21% · Health risk score 1.84. At or below the middle of the specialty; the typical hematology-oncology clinician is at 2.04.
Conditions among them: High blood pressure 71% · Cancer 49% · Diabetes 30% · Coronary heart disease 27% · Chronic kidney disease 27% · Atrial fibrillation 22% · Depression 20% · Heart failure 17% · COPD 12% · Dementia 9% · Stroke 8%.
The office billed $6,756,609, Medicare allowed $2,425,720 and paid $1,927,883; for 103,008 services of 116 kinds; $1,674,771 of it was for drugs given in the office and $253,112 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 586 | 103,008 | 77 | 1.84 | $6,756,609 | $1,927,883 |
| 2023 | 567 | 124,328 | 77 | 1.87 | $7,041,175 | $1,957,973 |
| 2022 | 517 | 92,803 | 76 | 1.79 | $5,701,614 | $1,669,236 |
| 2021 | 423 | 89,394 | 76 | 1.85 | $6,599,649 | $1,993,013 |
| 2020 | 394 | 87,946 | 76 | 1.83 | $6,201,560 | $1,800,356 |
| 2019 | 416 | 117,170 | 75 | 1.97 | $4,846,594 | $1,449,138 |
| 2018 | 390 | 135,529 | 75 | 1.99 | $5,396,140 | $1,617,210 |
| 2017 | 416 | 118,543 | 75 | 2.10 | $5,067,861 | $1,511,923 |
| 2016 | 409 | 106,080 | 75 | 2.18 | $4,321,212 | $1,341,620 |
| 2015 | 256 | 61,876 | 75 | 2.33 | $2,575,370 | $843,680 |
| 2014 | 248 | 29,405 | 74 | 2.10 | $1,618,142 | $556,442 |
| 2013 | 202 | 18,245 | 73 | 2.01 | $939,721 | $310,507 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 36 services
| Injection, daratumumab, 10 mg and hyaluronidase-fihj | 14 | $288,427 | None |
| Injection, denosumab, 1 mg | 36 | $134,319 | None |
| Return visit (30+ min) | 353 | $88,559 | $109 |
| Administration of chemotherapy into vein, 1 hour or less | 90 | $53,139 | $138 |
| Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | 30 | $23,761 | None |
| Long return visit (40+ min) | 88 | $22,614 | $158 |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 38 | $11,840 | None |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 18 | $10,729 | $76 |
| Telephone medical discussion with physician, 21-30 minutes | 71 | $8,358 | $83 |
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 22 | $8,312 | $0 |
| New patient visit (45+ min) | 55 | $7,829 | $142 |
| Administration of additional new drug or substance into vein, 1 hour or less | 31 | $6,854 | $68 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 47 | $6,655 | $30 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 33 | $5,644 | $71 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 196 | $5,555 | $8 |
| Injection of drug or substance under skin or into muscle | 102 | $4,262 | $13 |
| Short return visit (20+ min) | 40 | $3,952 | $76 |
| Injection of additional new drug or substance into vein | 65 | $3,513 | $16 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 12 | $3,509 | $66 |
| Administration of additional new drug or substance into vein using push technique | 15 | $3,366 | $58 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 28 | $3,238 | $116 |
| Administration of chemotherapy into vein, each additional hour | 24 | $3,175 | $29 |
| Biopsy and aspiration of bone marrow sample for diagnosis | 13 | $2,312 | $178 |
| Injection of drug or substance into vein | 33 | $2,098 | $37 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 15 | $1,620 | $34 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 12 | $1,561 | None |
| Application of on-body injector for under skin injection | 26 | $1,024 | $19 |
| Injection, palonosetron hcl, 25 mcg | 45 | $801 | None |
| Telephone medical discussion with physician, 11-20 minutes | 12 | $709 | $55 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 11 | $563 | None |
| Injection, carboplatin, 50 mg | 12 | $221 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 47 | $175 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 26 | $77 | None |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 13 | $36 | None |
| Unclassified drugs | 21 | $25 | None |
| Injection, midazolam hydrochloride, per 1 mg | 11 | $7 | None |
2022: 49 services
| Injection, denosumab, 1 mg | 42 | $174,442 | None |
| Injection, pembrolizumab, 1 mg | 13 | $143,154 | None |
| Return visit (30+ min) | 291 | $64,734 | $107 |
| Administration of chemotherapy into vein, 1 hour or less | 91 | $61,639 | $141 |
| Long return visit (40+ min) | 153 | $42,452 | $155 |
| Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | 26 | $31,401 | None |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 14 | $18,919 | None |
| Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | 12 | $15,754 | $33 |
| Administration of additional new drug or substance into vein, 1 hour or less | 40 | $11,162 | $69 |
| Telephone medical discussion with physician, 21-30 minutes | 83 | $11,035 | $89 |
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 15 | $9,414 | $1 |
| Short return visit (20+ min) | 85 | $8,492 | $80 |
| Administration of chemotherapy into vein, each additional hour | 43 | $8,178 | $29 |
| New patient visit (45+ min) | 57 | $8,123 | $143 |
| Injection of additional new drug or substance into vein | 79 | $7,021 | $16 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 58 | $6,658 | $30 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 177 | $6,063 | $8 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 11 | $5,708 | $76 |
| Injection of drug or substance under skin or into muscle | 89 | $4,771 | $13 |
| Injection of drug or substance into vein | 54 | $4,115 | $39 |
| Administration of additional new drug or substance into vein using push technique | 18 | $3,872 | $60 |
| Extended patient service without direct patient contact, first hour | 37 | $3,357 | $86 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 20 | $2,954 | $63 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 14 | $2,795 | None |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 17 | $2,782 | $32 |
| Biopsy of bone marrow | 16 | $2,639 | $165 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 14 | $2,447 | $175 |
| New patient visit (60+ min) | 12 | $2,443 | $204 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 18 | $2,135 | $119 |
| Aspiration of bone marrow sample for diagnosis | 16 | $1,268 | $79 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 11 | $1,266 | $90 |
| Infusion into a vein for hydration, 31-60 minutes | 12 | $810 | $35 |
| Insertion of needle into vein for collection of blood sample | 94 | $767 | $3 |
| Application of on-body injector for under skin injection | 20 | $759 | $19 |
| Injection, palonosetron hcl, 25 mcg | 44 | $755 | None |
| Telephone medical discussion with physician, 11-20 minutes | 11 | $730 | $66 |
| Short return visit | 15 | $656 | $44 |
| Injection, fluorouracil, 500 mg | 13 | $445 | None |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 11 | $337 | None |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 12 | $327 | $22 |
| Injection, carboplatin, 50 mg | 13 | $229 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 55 | $223 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 37 | $129 | None |
| Infusion, normal saline solution , 1000 cc | 13 | $52 | None |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 12 | $44 | None |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 12 | $40 | None |
| Injection, heparin sodium, (heparin lock flush), per 10 units | 24 | $37 | None |
| Unclassified drugs | 29 | $36 | None |
| Injection, midazolam hydrochloride, per 1 mg | 15 | $9 | None |
2021: 44 services
| Injection, pembrolizumab, 1 mg | 14 | $323,740 | None |
| Injection, denosumab, 1 mg | 30 | $134,359 | None |
| Return visit (30+ min) | 247 | $60,057 | $111 |
| Administration of chemotherapy into vein, 1 hour or less | 68 | $50,495 | $152 |
| Injection, pegfilgrastim, 6 mg | 22 | $33,943 | None |
| Long return visit (40+ min) | 108 | $33,776 | $168 |
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 13 | $10,592 | $1 |
| Telephone medical discussion with physician, 21-30 minutes | 59 | $9,951 | $116 |
| Administration of additional new drug or substance into vein, 1 hour or less | 26 | $7,257 | $74 |
| Short return visit (20+ min) | 58 | $7,173 | $83 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 47 | $5,884 | $31 |
| New patient visit (45+ min) | 36 | $5,239 | $146 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 165 | $5,237 | $8 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 13 | $4,424 | None |
| Injection of additional new drug or substance into vein | 58 | $4,192 | $17 |
| Injection of drug or substance under skin or into muscle | 78 | $3,901 | $13 |
| Administration of additional new drug or substance into vein using push technique | 13 | $3,899 | $62 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 27 | $3,880 | $64 |
| Administration of chemotherapy into vein, each additional hour | 20 | $3,855 | $32 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 19 | $3,527 | $73 |
| Injection of drug or substance into vein | 36 | $3,045 | $41 |
| Aspiration of bone marrow sample for diagnosis | 14 | $3,000 | $167 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 18 | $2,950 | $32 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 15 | $2,687 | $179 |
| New patient visit (60+ min) | 13 | $2,517 | $194 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 20 | $2,218 | $92 |
| Extended patient service without direct patient contact, first hour | 23 | $2,209 | $96 |
| Short return visit | 30 | $1,787 | $51 |
| Biopsy of bone marrow | 14 | $1,483 | $82 |
| Injection, palonosetron hcl, 25 mcg | 34 | $1,428 | None |
| Application of on-body injector for under skin injection | 21 | $1,045 | $20 |
| Telephone medical discussion with physician, 11-20 minutes | 11 | $1,043 | $87 |
| Insertion of needle into vein for collection of blood sample | 93 | $915 | $3 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 16 | $904 | $22 |
| Telephone medical discussion with physician, 5-10 minutes | 12 | $598 | $50 |
| Injection, carboplatin, 50 mg | 11 | $270 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 42 | $238 | None |
| Infusion, normal saline solution , 1000 cc | 13 | $83 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 20 | $54 | None |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 18 | $52 | None |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 12 | $46 | None |
| Injection, heparin sodium, (heparin lock flush), per 10 units | 20 | $34 | None |
| Unclassified drugs | 18 | $17 | None |
| Injection, midazolam hydrochloride, per 1 mg | 12 | $7 | None |
2020: 34 services
| Injection, pembrolizumab, 1 mg | 11 | $167,232 | None |
| Injection, denosumab, 1 mg | 32 | $96,587 | None |
| Return visit (30+ min) | 246 | $59,396 | $98 |
| Administration of chemotherapy into vein, 1 hour or less | 68 | $51,462 | $146 |
| Long return visit (40+ min) | 85 | $18,236 | $132 |
| Injection, pegfilgrastim, 6 mg | 15 | $15,521 | None |
| Unclassified drugs | 16 | $8,770 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 47 | $7,631 | $31 |
| Short return visit (20+ min) | 80 | $7,115 | $67 |
| New patient visit (45+ min) | 45 | $6,855 | $152 |
| Administration of additional new drug or substance into vein, 1 hour or less | 27 | $6,293 | $72 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 11 | $5,408 | $82 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 155 | $5,182 | $8 |
| Injection of additional new drug or substance into vein | 61 | $5,059 | $16 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 34 | $4,991 | $67 |
| Injection, palonosetron hcl, 25 mcg | 33 | $4,156 | None |
| Injection of drug or substance under skin or into muscle | 70 | $3,877 | $13 |
| Administration of chemotherapy into vein, each additional hour | 26 | $3,510 | $31 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 15 | $2,786 | $186 |
| Administration of additional new drug or substance into vein using push technique | 14 | $2,708 | $59 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 12 | $2,468 | $75 |
| Aspiration of bone marrow sample for diagnosis | 13 | $2,226 | $171 |
| Injection of drug or substance into vein | 31 | $2,021 | $39 |
| Telephone medical discussion with physician, 21-30 minutes | 15 | $1,895 | $105 |
| Extended patient service without direct patient contact, first hour | 18 | $1,853 | $103 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 15 | $1,521 | None |
| Biopsy of bone marrow | 13 | $1,049 | $81 |
| Insertion of needle into vein for collection of blood sample | 85 | $891 | $3 |
| Application of on-body injector for under skin injection | 13 | $403 | $20 |
| Brief communication technology-based service, e.g. virtual check-in, by a physician or other qualified health care professional who can report evaluation and management services, provided to an established patient, not originating from a related e/m servic | 22 | $298 | $13 |
| Injection, dexamethasone sodium phosphate, 1 mg | 46 | $252 | None |
| Injection, heparin sodium, (heparin lock flush), per 10 units | 17 | $196 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 21 | $46 | None |
| Injection, midazolam hydrochloride, per 1 mg | 12 | $6 | None |
2019: 36 services
| Injection, pembrolizumab, 1 mg | 14 | $270,533 | None |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 13 | $78,040 | None |
| Return visit (30+ min) | 256 | $69,581 | $95 |
| Injection, denosumab, 1 mg | 31 | $69,001 | None |
| Administration of chemotherapy into vein, 1 hour or less | 66 | $47,494 | $144 |
| Long return visit (40+ min) | 66 | $12,157 | $134 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 54 | $11,812 | $65 |
| Injection, palonosetron hcl, 25 mcg | 31 | $10,573 | None |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 185 | $7,166 | $8 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 41 | $6,777 | $32 |
| Short return visit (20+ min) | 66 | $6,440 | $69 |
| New patient visit (45+ min) | 45 | $6,206 | $138 |
| Injection of drug or substance under skin or into muscle | 71 | $5,701 | $16 |
| Administration of additional new drug or substance into vein, 1 hour or less | 20 | $5,344 | $70 |
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 11 | $5,126 | $1 |
| Injection of additional new drug or substance into vein | 51 | $3,525 | $17 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 17 | $3,084 | $181 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 23 | $2,814 | $122 |
| Administration of chemotherapy into vein, each additional hour | 19 | $2,676 | $31 |
| Infusion into a vein for hydration, 31-60 minutes | 20 | $2,372 | $38 |
| Aspiration of bone marrow sample for diagnosis | 12 | $1,992 | $166 |
| Extended patient service without direct patient contact, first hour | 17 | $1,711 | $101 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 11 | $1,602 | $31 |
| Injection of drug or substance into vein | 26 | $1,278 | $40 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 11 | $1,186 | $74 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 11 | $1,026 | $93 |
| Biopsy of bone marrow | 12 | $886 | $74 |
| Insertion of needle into vein for collection of blood sample | 82 | $682 | $3 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 20 | $637 | $21 |
| Injection, heparin sodium, (heparin lock flush), per 10 units | 18 | $454 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 36 | $200 | None |
| Infusion, normal saline solution , 1000 cc | 21 | $125 | None |
| Unclassified drugs | 18 | $59 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 22 | $40 | None |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 11 | $25 | None |
| Injection, midazolam hydrochloride, per 1 mg | 12 | $6 | None |
2018: 45 services
| Injection, bevacizumab, 10 mg | 14 | $330,237 | None |
| Injection, rituximab, 100 mg | 12 | $146,352 | None |
| Return visit (30+ min) | 231 | $63,220 | $89 |
| Injection, denosumab, 1 mg | 24 | $57,504 | None |
| Administration of chemotherapy into vein, 1 hour or less | 69 | $51,439 | $138 |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 11 | $34,460 | None |
| Injection, palonosetron hcl, 25 mcg | 43 | $25,149 | None |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 64 | $17,453 | $63 |
| Injection, pegfilgrastim, 6 mg | 13 | $14,414 | None |
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 15 | $11,420 | $1 |
| Other chemotherapy procedure | 19 | $10,020 | $162 |
| Administration of additional new drug or substance into vein, 1 hour or less | 33 | $8,532 | $68 |
| Injection, fosaprepitant, 1 mg | 14 | $8,136 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 51 | $7,849 | $31 |
| Injection, levoleucovorin, not otherwise specified, 0.5 mg | 13 | $7,326 | None |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 174 | $6,975 | $9 |
| New patient visit (45+ min) | 45 | $6,167 | $137 |
| Short return visit (20+ min) | 66 | $5,639 | $63 |
| Injection of additional new drug or substance into vein | 60 | $5,135 | $17 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 20 | $4,220 | $70 |
| Long return visit (40+ min) | 36 | $4,179 | $116 |
| Injection of drug or substance under skin or into muscle | 55 | $4,176 | $19 |
| Administration of chemotherapy into vein, each additional hour | 32 | $4,139 | $30 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 26 | $3,188 | $114 |
| Infusion into a vein for hydration, 31-60 minutes | 24 | $2,913 | $43 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 12 | $2,895 | None |
| New patient visit (60+ min) | 15 | $2,606 | $174 |
| Aspiration of bone marrow sample for diagnosis | 13 | $2,114 | $163 |
| Injection, oxaliplatin, 0.5 mg | 12 | $2,010 | None |
| Administration of additional new drug or substance into vein using push technique | 11 | $1,512 | $58 |
| Injection of drug or substance into vein | 21 | $1,420 | $46 |
| Hospital discharge day management, 30 minutes or less | 16 | $1,412 | $64 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 25 | $904 | $19 |
| Biopsy of bone marrow | 13 | $883 | $68 |
| Insertion of needle into vein for collection of blood sample | 82 | $732 | $3 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 15 | $640 | $20 |
| Injection, carboplatin, 50 mg | 11 | $509 | None |
| Application of on-body injector for under skin injection | 11 | $436 | $19 |
| Injection, heparin sodium, (heparin lock flush), per 10 units | 20 | $398 | None |
| Injection, fluorouracil, 500 mg | 20 | $375 | None |
| Unclassified drugs | 23 | $311 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 44 | $189 | None |
| Infusion, normal saline solution , 1000 cc | 26 | $151 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 26 | $45 | None |
| Injection, midazolam hydrochloride, per 1 mg | 13 | $6 | None |
2017: 45 services
| Injection, bevacizumab, 10 mg | 20 | $235,301 | None |
| Return visit (30+ min) | 207 | $57,973 | $94 |
| Administration of chemotherapy into vein, 1 hour or less | 78 | $44,394 | $143 |
| Injection, denosumab, 1 mg | 16 | $40,479 | None |
| Injection, pegfilgrastim, 6 mg | 15 | $34,260 | None |
| Injection, palonosetron hcl, 25 mcg | 48 | $30,348 | None |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 97 | $29,376 | $65 |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 14 | $29,070 | None |
| Injection, levoleucovorin, not otherwise specified, 0.5 mg | 12 | $15,754 | None |
| Other chemotherapy procedure | 18 | $9,552 | $162 |
| New patient visit (45+ min) | 64 | $9,352 | $146 |
| Injection, fosaprepitant, 1 mg | 14 | $8,326 | None |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 180 | $7,660 | $10 |
| Administration of additional new drug or substance into vein, 1 hour or less | 34 | $7,331 | $66 |
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 13 | $6,716 | $1 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 57 | $6,381 | $31 |
| Injection of additional new drug or substance into vein | 57 | $5,940 | $23 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 40 | $5,622 | $120 |
| Injection of drug or substance under skin or into muscle | 61 | $5,324 | $25 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 21 | $5,197 | $70 |
| Short return visit (20+ min) | 61 | $4,941 | $69 |
| Long return visit (40+ min) | 33 | $4,735 | $132 |
| New patient visit (60+ min) | 18 | $3,279 | $182 |
| Administration of chemotherapy into vein, each additional hour | 28 | $3,167 | $29 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 18 | $2,961 | None |
| Infusion into a vein for hydration, 31-60 minutes | 19 | $2,645 | $60 |
| Administration of additional new drug or substance into vein using push technique | 16 | $2,325 | $65 |
| Aspiration of bone marrow sample for diagnosis | 12 | $2,207 | $170 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 11 | $1,990 | $181 |
| Hospital discharge day management, 30 minutes or less | 20 | $1,667 | $64 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 47 | $1,527 | $18 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 14 | $1,254 | $90 |
| Biopsy of bone marrow | 12 | $1,099 | $85 |
| Injection, carboplatin, 50 mg | 16 | $996 | None |
| Injection of drug or substance into vein | 13 | $891 | $56 |
| Injection, heparin sodium, (heparin lock flush), per 10 units | 34 | $803 | None |
| Insertion of needle into vein for collection of blood sample | 87 | $614 | $3 |
| Injection, fluorouracil, 500 mg | 20 | $593 | None |
| Blood test, clotting time | 11 | $248 | $5 |
| Unclassified drugs | 15 | $206 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 53 | $183 | None |
| Infusion, normal saline solution , 1000 cc | 17 | $70 | None |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 17 | $28 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 17 | $24 | None |
| Injection, midazolam hydrochloride, per 1 mg | 11 | $6 | None |
2016: 35 services
| Injection, bevacizumab, 10 mg | 11 | $158,594 | None |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 20 | $64,771 | None |
| Return visit (30+ min) | 190 | $53,776 | $93 |
| Injection, pegfilgrastim, 6 mg | 12 | $49,070 | None |
| Administration of chemotherapy into vein, 1 hour or less | 70 | $40,513 | $142 |
| Injection, denosumab, 1 mg | 15 | $28,915 | None |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 83 | $21,322 | $65 |
| Injection, palonosetron hcl, 25 mcg | 43 | $19,547 | None |
| Injection, levoleucovorin, not otherwise specified, 0.5 mg | 11 | $13,138 | None |
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 13 | $9,089 | $1 |
| New patient visit (45+ min) | 58 | $8,580 | $148 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 177 | $7,463 | $10 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 54 | $6,186 | $31 |
| Short return visit (20+ min) | 63 | $5,426 | $65 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 37 | $4,911 | $120 |
| Injection of drug or substance under skin or into muscle | 58 | $4,745 | $25 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 18 | $4,460 | $71 |
| New patient visit (60+ min) | 23 | $4,183 | $182 |
| Injection of additional new drug or substance into vein | 48 | $3,817 | $23 |
| Administration of additional new drug or substance into vein, 1 hour or less | 25 | $3,767 | $65 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 23 | $3,305 | $77 |
| Long return visit (40+ min) | 22 | $2,938 | $134 |
| Injection of drug or substance into vein | 26 | $2,481 | $59 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 14 | $2,452 | None |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 11 | $1,996 | $181 |
| Administration of chemotherapy into vein, each additional hour | 23 | $1,624 | $28 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 24 | $780 | $20 |
| Injection, carboplatin, 50 mg | 13 | $748 | None |
| Insertion of needle into vein for collection of blood sample | 68 | $550 | $3 |
| Injection, heparin sodium, (heparin lock flush), per 10 units | 22 | $328 | None |
| Blood test, clotting time | 15 | $289 | $5 |
| Injection, fluorouracil, 500 mg | 13 | $262 | None |
| Unclassified drugs | 12 | $253 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 49 | $187 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 15 | $17 | None |
2015: 26 services
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 15 | $67,361 | None |
| Return visit (30+ min) | 143 | $51,587 | $96 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 85 | $26,598 | $65 |
| Administration of chemotherapy into vein, 1 hour or less | 23 | $24,946 | $143 |
| Injection, palonosetron hcl, 25 mcg | 16 | $14,284 | None |
| Short return visit (20+ min) | 59 | $7,252 | $69 |
| New patient visit (60+ min) | 35 | $6,457 | $184 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 83 | $6,378 | $10 |
| New patient visit (45+ min) | 38 | $5,625 | $148 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 20 | $4,440 | $31 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 16 | $3,888 | $73 |
| Biopsy of bone marrow | 21 | $3,762 | $171 |
| Administration of additional new drug or substance into vein, 1 hour or less | 11 | $3,436 | $66 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 23 | $2,664 | $89 |
| Injection of drug or substance under skin or into muscle | 20 | $2,650 | $26 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 20 | $2,456 | $123 |
| Administration of chemotherapy into vein, each additional hour | 12 | $2,400 | $29 |
| Long return visit (40+ min) | 17 | $2,350 | $131 |
| Aspiration of bone marrow sample for diagnosis | 21 | $1,859 | $84 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 27 | $1,421 | $19 |
| Injection of additional new drug or substance into vein | 17 | $1,336 | $23 |
| Injection of drug or substance into vein | 11 | $902 | $60 |
| Unclassified drugs | 22 | $717 | None |
| Insertion of needle into vein for collection of blood sample | 55 | $444 | $3 |
| Injection, dexamethasone sodium phosphate, 1 mg | 14 | $118 | None |
| Injection, midazolam hydrochloride, per 1 mg | 19 | $10 | None |
2014: 22 services
| Return visit (30+ min) | 91 | $24,119 | $100 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 86 | $23,259 | $64 |
| Short return visit (20+ min) | 88 | $12,509 | $62 |
| Administration of chemotherapy into vein, 1 hour or less | 16 | $12,456 | $140 |
| New patient visit (45+ min) | 61 | $8,767 | $144 |
| New patient visit (60+ min) | 38 | $6,977 | $184 |
| Injection, palonosetron hcl, 25 mcg | 11 | $6,893 | None |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 35 | $4,279 | $122 |
| Biopsy of bone marrow | 19 | $3,677 | $167 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 61 | $3,619 | $10 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 30 | $3,138 | $90 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 12 | $2,198 | $67 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 25 | $1,852 | $20 |
| Aspiration of bone marrow sample for diagnosis | 19 | $1,789 | $81 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 14 | $1,774 | $31 |
| Injection of drug or substance under skin or into muscle | 18 | $1,470 | $24 |
| Injection of additional new drug or substance into vein | 20 | $1,324 | $23 |
| Injection of drug or substance into vein | 12 | $829 | $55 |
| Insertion of needle into vein for collection of blood sample | 29 | $188 | $3 |
| Unclassified drugs | 18 | $71 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 13 | $59 | None |
| Injection, midazolam hydrochloride, per 1 mg | 16 | $10 | None |
2013: 16 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 79 | $20,785 | $62 |
| Short return visit (20+ min) | 79 | $20,454 | $66 |
| Administration of chemotherapy into vein, 1 hour or less | 12 | $10,626 | $150 |
| New patient visit (60+ min) | 40 | $7,464 | $187 |
| New patient visit (45+ min) | 39 | $5,656 | $145 |
| Return visit (30+ min) | 22 | $3,627 | $98 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 28 | $3,603 | $116 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 37 | $3,549 | $83 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 41 | $2,418 | $11 |
| Injection of drug or substance under skin or into muscle | 14 | $1,487 | $26 |
| Injection of drug or substance into vein | 14 | $1,484 | $59 |
| Injection of additional new drug or substance into vein | 15 | $1,449 | $23 |
| Short return visit | 31 | $1,438 | $41 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 20 | $1,151 | $19 |
| Insertion of needle into vein for collection of blood sample | 16 | $77 | $3 |
| Injection, dexamethasone sodium phosphate, 1 mg | 11 | $43 | None |
Medicaid work
$16,526 in 2024
Medicaid paid $16,526 for 411 billed services this clinician did in 2024, up to 30 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 191 | $15,089 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 193 | $907 |
| Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug | 13 | $317 |
| Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular | 14 | $213 |
| 2024 | 411 | 4 | 30 | $16,526 |
| 2023 | 162 | 2 | 24 | $3,987 |
| 2022 | 185 | 3 | 20 | $3,951 |
| 2021 | 232 | 2 | 20 | $2,044 |
| 2020 | 240 | 2 | 19 | $2,550 |
| 2019 | 276 | 2 | 20 | $737 |
| 2018 | 61 | 2 | 18 | $158 |
See the largest Medicaid services in earlier years
2023
| Return visit (30+ min) | 57 | $3,409 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 105 | $579 |
2022
| Return visit (30+ min) | 53 | $3,423 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 119 | $473 |
| Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular | 13 | $55 |
2021
| Return visit (30+ min) | 68 | $1,599 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 164 | $444 |
2020
| Return visit (30+ min) | 110 | $2,337 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 130 | $214 |
2019
| Return visit (30+ min) | 52 | $484 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 224 | $253 |
2018
| Return visit (30+ min) | 19 | $152 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 42 | $7 |
Drugs they prescribed that Part D paid
$8,298,907
Pharmacies billed $8,298,907 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 2% of their Part D prescriptions (39 of 1,659) in 2024. At or below the middle of the specialty; the typical hematology-oncology clinician is at 5%.
817 generic and 842 brand-name prescriptions · $8,298,907 in drug cost · 85 antibiotic prescriptions to 17 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Revlimid | 79 | $1,142,710 | $14,465 |
| Darzalex Faspro | 62 | $586,601 | $9,461 |
| Tagrisso | 32 | $519,602 | $16,238 |
| Pomalyst | 27 | $482,368 | $17,865 |
| Jakafi | 33 | $451,305 | $13,676 |
See all 41 drugs
| Revlimid | 79 | $1,142,710 | $14,465 |
| Darzalex Faspro | 62 | $586,601 | $9,461 |
| Tagrisso | 32 | $519,602 | $16,238 |
| Pomalyst | 27 | $482,368 | $17,865 |
| Jakafi | 33 | $451,305 | $13,676 |
| Lenalidomide | 36 | $436,082 | $12,113 |
| Ojjaara | 15 | $420,327 | $28,022 |
| Ibrance | 24 | $376,546 | $15,689 |
| Tasigna | 18 | $347,888 | $19,327 |
| Venclexta | 54 | $257,990 | $4,778 |
| Lynparza | 13 | $206,455 | $15,881 |
| Imbruvica | 12 | $190,213 | $15,851 |
| Xgeva | 58 | $185,063 | $3,191 |
| Tavalisse | 12 | $178,526 | $14,877 |
| Enhertu | 14 | $113,694 | $8,121 |
| Neulasta Onpro | 17 | $105,945 | $6,232 |
| Aranesp | 47 | $103,477 | $2,202 |
| Lupron Depot | 17 | $100,723 | $5,925 |
| Herceptin | 18 | $84,589 | $4,699 |
| Azacitidine | 18 | $50,234 | $2,791 |
| Promacta | 13 | $49,294 | $3,792 |
| Eliquis | 43 | $34,992 | $814 |
| Xarelto | 34 | $30,715 | $903 |
| Abiraterone Acetate | 26 | $28,612 | $1,100 |
| Decitabine | 13 | $4,264 | $328 |
| Fulvestrant | 13 | $3,750 | $288 |
| Hydroxyurea | 109 | $2,154 | $20 |
| Anastrozole | 57 | $2,015 | $35 |
| Letrozole | 44 | $1,864 | $42 |
| Tamoxifen Citrate | 32 | $1,155 | $36 |
| Dexamethasone | 38 | $743 | $20 |
| Ondansetron | 29 | $669 | $23 |
| Valacyclovir | 11 | $663 | $60 |
| Acyclovir | 47 | $573 | $12 |
| Oxycodone | 18 | $450 | $25 |
| Sulfamethoxazole-Trimethoprim | 75 | $311 | $4 |
| Warfarin | 14 | $172 | $12 |
| Prochlorperazine Maleate | 13 | $135 | $10 |
| Allopurinol | 11 | $124 | $11 |
| Furosemide | 11 | $114 | $10 |
| Prednisone | 24 | $99 | $4 |
Year by year
| 2024 | 1,659 | 207 | 2% (39) | 51% | $8,298,907 |
| 2023 | 2,167 | 215 | 1% (30) | 53% | $11,568,219 |
| 2022 | 2,491 | 243 | 1% (25) | 53% | $12,344,863 |
| 2021 | 2,184 | 205 | 2% (39) | 46% | $8,573,795 |
| 2020 | 2,044 | 202 | 2% (46) | 52% | $8,292,254 |
| 2019 | 1,802 | 192 | 3% (60) | 55% | $6,418,136 |
| 2018 | 1,437 | 176 | 5% (67) | None | $4,127,246 |
| 2017 | 1,386 | 162 | 5% (63) | 40% | $3,144,368 |
| 2016 | 1,003 | 136 | 7% (65) | None | $2,040,347 |
| 2015 | 823 | 112 | 7% (60) | None | $1,091,625 |
| 2014 | 771 | 105 | 17% (127) | 24% | $758,081 |
| 2013 | 647 | 81 | 12% (78) | None | $451,613 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 64 drugs
| Revlimid | 81 | $1,461,982 | $18,049 |
| Jakafi | 49 | $695,760 | $14,199 |
| Darzalex Faspro | 62 | $615,875 | $9,933 |
| Ibrance | 36 | $553,119 | $15,364 |
| Cabometyx | 18 | $486,478 | $27,027 |
| Tagrisso | 23 | $424,549 | $18,459 |
| Tibsovo | 13 | $418,033 | $32,156 |
| Tabrecta | 17 | $360,442 | $21,202 |
| Neulasta Onpro | 51 | $355,121 | $6,963 |
| Onureg | 13 | $338,397 | $26,031 |
| Xgeva | 100 | $310,728 | $3,107 |
| Tasigna | 16 | $297,420 | $18,589 |
| Opdivo | 22 | $268,816 | $12,219 |
| Pomalyst | 17 | $255,775 | $15,046 |
| Venclexta | 48 | $249,975 | $5,208 |
| Reblozyl | 15 | $241,282 | $16,085 |
| Tecentriq | 22 | $240,553 | $10,934 |
| Imbruvica | 14 | $235,306 | $16,808 |
| Lynparza | 12 | $201,322 | $16,777 |
| Verzenio | 12 | $189,736 | $15,811 |
| Aranesp | 72 | $187,542 | $2,605 |
| Keytruda | 16 | $187,178 | $11,699 |
| Nplate | 27 | $176,453 | $6,535 |
| Nubeqa | 12 | $173,721 | $14,477 |
| Tavalisse | 12 | $168,521 | $14,043 |
| Abiraterone Acetate | 18 | $150,148 | $8,342 |
| Avastin | 17 | $144,543 | $8,503 |
| Abraxane | 12 | $124,714 | $10,393 |
| Somatuline Depot | 12 | $122,557 | $10,213 |
| Lupron Depot | 18 | $114,109 | $6,339 |
| Enhertu | 12 | $105,813 | $8,818 |
| Imfinzi | 11 | $102,340 | $9,304 |
| Ruxience | 11 | $85,817 | $7,802 |
| Herceptin | 17 | $84,898 | $4,994 |
| Trazimera | 13 | $51,015 | $3,924 |
| Eliquis | 59 | $40,593 | $688 |
| Promacta | 11 | $39,423 | $3,584 |
| Imatinib Mesylate | 13 | $31,973 | $2,459 |
| Fulvestrant | 39 | $29,350 | $753 |
| Decitabine | 12 | $27,651 | $2,304 |
| Xarelto | 19 | $22,681 | $1,194 |
| Prolia | 11 | $18,853 | $1,714 |
| Azacitidine | 24 | $9,521 | $397 |
| Hydroxyurea | 114 | $5,013 | $44 |
| Anastrozole | 94 | $3,128 | $33 |
| Gemcitabine | 11 | $2,660 | $242 |
| Palonosetron | 26 | $1,501 | $58 |
| Tamoxifen Citrate | 39 | $1,464 | $38 |
| Letrozole | 38 | $1,259 | $33 |
| Sulfamethoxazole-Trimethoprim | 89 | $1,193 | $13 |
| Acyclovir | 72 | $1,024 | $14 |
| Valacyclovir | 14 | $617 | $44 |
| Gabapentin | 20 | $377 | $19 |
| Ondansetron Odt | 11 | $370 | $34 |
| Dexamethasone | 22 | $329 | $15 |
| Prednisone | 19 | $312 | $16 |
| Ondansetron | 28 | $244 | $9 |
| Fluconazole | 11 | $212 | $19 |
| Prochlorperazine Maleate | 20 | $205 | $10 |
| Levothyroxine | 13 | $149 | $11 |
| Furosemide | 11 | $124 | $11 |
| Warfarin | 12 | $119 | $10 |
| Lorazepam | 17 | $114 | $7 |
| Folic Acid | 11 | $29 | $3 |
2022: 69 drugs
| Revlimid | 68 | $1,175,600 | $17,288 |
| Ibrance | 71 | $1,043,123 | $14,692 |
| Jakafi | 44 | $676,409 | $15,373 |
| Pomalyst | 35 | $654,307 | $18,694 |
| Cabometyx | 23 | $581,061 | $25,264 |
| Neulasta Onpro | 62 | $425,158 | $6,857 |
| Imbruvica | 26 | $414,600 | $15,946 |
| Tagrisso | 22 | $366,147 | $16,643 |
| Tibsovo | 12 | $360,633 | $30,053 |
| Xgeva | 121 | $344,328 | $2,846 |
| Darzalex Faspro | 37 | $332,875 | $8,997 |
| Opdivo | 20 | $299,291 | $14,965 |
| Onureg | 12 | $288,936 | $24,078 |
| Keytruda | 25 | $284,302 | $11,372 |
| Tabrecta | 13 | $255,334 | $19,641 |
| Tasigna | 13 | $240,951 | $18,535 |
| Aranesp | 95 | $234,836 | $2,472 |
| Kyprolis | 14 | $222,590 | $15,899 |
| Zirabev | 28 | $221,699 | $7,918 |
| Reblozyl | 14 | $216,606 | $15,472 |
| Avastin | 24 | $215,159 | $8,965 |
| Gazyva | 20 | $208,345 | $10,417 |
| Lynparza | 13 | $206,359 | $15,874 |
| Darzalex | 24 | $203,670 | $8,486 |
| Tavalisse | 15 | $195,912 | $13,061 |
| Abraxane | 23 | $163,707 | $7,118 |
| Abiraterone Acetate | 24 | $153,006 | $6,375 |
| Venclexta | 42 | $151,497 | $3,607 |
| Nplate | 20 | $142,013 | $7,101 |
| Tecentriq | 12 | $127,646 | $10,637 |
| Alimta | 15 | $123,568 | $8,238 |
| Somatuline Depot | 12 | $118,280 | $9,857 |
| Phesgo | 11 | $104,582 | $9,507 |
| Promacta | 15 | $86,461 | $5,764 |
| Herceptin | 17 | $84,898 | $4,994 |
| Pemetrexed Disodium | 12 | $60,287 | $5,024 |
| Imatinib Mesylate | 27 | $51,410 | $1,904 |
| Trazimera | 12 | $50,865 | $4,239 |
| Fulvestrant | 51 | $48,420 | $949 |
| Eliquis | 54 | $33,921 | $628 |
| Xarelto | 22 | $24,200 | $1,100 |
| Prolia | 15 | $23,227 | $1,548 |
| Creon | 18 | $18,371 | $1,021 |
| Azacitidine | 22 | $15,641 | $711 |
| Akynzeo | 19 | $13,985 | $736 |
| Palonosetron | 81 | $6,384 | $79 |
| Gemcitabine | 30 | $6,246 | $208 |
| Hydroxyurea | 108 | $4,137 | $38 |
| Fosaprepitant Dimeglumine | 15 | $3,712 | $247 |
| Anastrozole | 120 | $3,142 | $26 |
| Oxaliplatin | 13 | $2,133 | $164 |
| Leucovorin | 15 | $1,781 | $119 |
| Carboplatin | 39 | $1,711 | $44 |
| Tamoxifen Citrate | 26 | $1,248 | $48 |
| Valacyclovir | 19 | $1,184 | $62 |
| Acyclovir | 47 | $866 | $18 |
| Mirtazapine | 19 | $863 | $45 |
| Letrozole | 21 | $838 | $40 |
| Dexamethasone | 60 | $761 | $13 |
| Sulfamethoxazole-Trimethoprim | 73 | $580 | $8 |
| Alprazolam | 12 | $533 | $44 |
| Ondansetron | 20 | $343 | $17 |
| Gabapentin | 16 | $224 | $14 |
| Prochlorperazine Maleate | 14 | $183 | $13 |
| Levothyroxine | 11 | $161 | $15 |
| Prednisone | 22 | $160 | $7 |
| Furosemide | 13 | $73 | $6 |
| Lorazepam | 15 | $72 | $5 |
| Methylprednisolone | 11 | $35 | $3 |
2021: 60 drugs
| Ibrance | 63 | $875,131 | $13,891 |
| Pomalyst | 39 | $736,761 | $18,891 |
| Jakafi | 31 | $566,758 | $18,283 |
| Imbruvica | 27 | $398,060 | $14,743 |
| Keytruda | 35 | $370,673 | $10,591 |
| Reblozyl | 23 | $363,706 | $15,813 |
| Avastin | 36 | $348,651 | $9,685 |
| Neulasta Onpro | 47 | $314,534 | $6,692 |
| Darzalex Faspro | 32 | $277,482 | $8,671 |
| Cabometyx | 12 | $274,778 | $22,898 |
| Venclexta | 69 | $271,942 | $3,941 |
| Tecentriq | 26 | $263,132 | $10,120 |
| Nplate | 46 | $244,775 | $5,321 |
| Tagrisso | 14 | $217,049 | $15,503 |
| Opdivo | 14 | $201,227 | $14,373 |
| Promacta | 24 | $193,043 | $8,043 |
| Lynparza | 12 | $182,056 | $15,171 |
| Aranesp | 65 | $180,008 | $2,769 |
| Revlimid | 12 | $177,360 | $14,780 |
| Somatuline Depot | 13 | $119,519 | $9,194 |
| Rituxan | 14 | $119,313 | $8,522 |
| Alimta | 15 | $118,927 | $7,928 |
| Xgeva | 38 | $99,720 | $2,624 |
| Herceptin | 17 | $84,898 | $4,994 |
| Abiraterone Acetate | 22 | $65,440 | $2,975 |
| Ruxience | 12 | $65,332 | $5,444 |
| Posaconazole | 12 | $49,186 | $4,099 |
| Fulvestrant | 37 | $48,090 | $1,300 |
| Azacitidine | 26 | $39,137 | $1,505 |
| Eliquis | 42 | $26,534 | $632 |
| Vemlidy | 11 | $14,285 | $1,299 |
| Akynzeo | 19 | $13,769 | $725 |
| Levoleucovorin | 18 | $12,649 | $703 |
| Xarelto | 15 | $12,541 | $836 |
| Imatinib Mesylate | 19 | $10,312 | $543 |
| Palonosetron | 61 | $10,060 | $165 |
| Oxaliplatin | 25 | $4,637 | $185 |
| Hydroxyurea | 92 | $4,209 | $46 |
| Anastrozole | 94 | $3,226 | $34 |
| Gemcitabine | 16 | $2,035 | $127 |
| Carboplatin | 48 | $1,562 | $33 |
| Valacyclovir | 19 | $1,212 | $64 |
| Acyclovir | 58 | $1,095 | $19 |
| Paclitaxel | 12 | $1,073 | $89 |
| Tamoxifen Citrate | 13 | $909 | $70 |
| Levofloxacin | 22 | $754 | $34 |
| Mirtazapine | 12 | $653 | $54 |
| Prochlorperazine Maleate | 41 | $645 | $16 |
| Letrozole | 31 | $614 | $20 |
| Hydrocodone-Acetaminophen | 17 | $552 | $32 |
| Lactated Ringers | 19 | $534 | $28 |
| Dexamethasone | 43 | $479 | $11 |
| Ondansetron | 28 | $455 | $16 |
| Sulfamethoxazole-Trimethoprim | 65 | $351 | $5 |
| Omeprazole | 18 | $294 | $16 |
| Prednisone | 36 | $288 | $8 |
| Gabapentin | 21 | $216 | $10 |
| Lorazepam | 14 | $171 | $12 |
| Allopurinol | 15 | $135 | $9 |
| Methylprednisolone | 14 | $105 | $7 |
2020: 51 drugs
| Pomalyst | 46 | $881,372 | $19,160 |
| Imbruvica | 54 | $677,602 | $12,548 |
| Tagrisso | 38 | $609,609 | $16,042 |
| Keytruda | 53 | $538,983 | $10,169 |
| Ibrance | 42 | $534,560 | $12,728 |
| Revlimid | 34 | $504,141 | $14,828 |
| Jakafi | 30 | $464,618 | $15,487 |
| Aranesp | 125 | $418,403 | $3,347 |
| Venclexta | 47 | $291,434 | $6,201 |
| Lynparza | 18 | $269,173 | $14,954 |
| Opdivo | 19 | $260,996 | $13,737 |
| Cabometyx | 12 | $246,079 | $20,507 |
| Neulasta Onpro | 33 | $209,293 | $6,342 |
| Reblozyl | 17 | $205,614 | $12,095 |
| Rituxan | 19 | $167,270 | $8,804 |
| Nplate | 37 | $151,227 | $4,087 |
| Xgeva | 57 | $137,055 | $2,404 |
| Halaven | 25 | $136,081 | $5,443 |
| Ninlaro | 12 | $134,727 | $11,227 |
| Somatuline Depot | 13 | $119,519 | $9,194 |
| Imfinzi | 26 | $62,105 | $2,389 |
| Herceptin | 12 | $59,254 | $4,938 |
| Velcade | 12 | $55,871 | $4,656 |
| Zarxio | 13 | $46,367 | $3,567 |
| Fulvestrant | 22 | $37,857 | $1,721 |
| Promacta | 12 | $33,227 | $2,769 |
| Eliquis | 56 | $29,403 | $525 |
| Vemlidy | 12 | $19,400 | $1,617 |
| Xarelto | 25 | $17,288 | $692 |
| Abiraterone Acetate | 13 | $6,836 | $526 |
| Gemcitabine | 29 | $5,239 | $181 |
| Hydroxyurea | 90 | $4,122 | $46 |
| Palonosetron | 36 | $4,034 | $112 |
| Anastrozole | 110 | $3,850 | $35 |
| Acyclovir | 59 | $1,362 | $23 |
| Carboplatin | 28 | $1,146 | $41 |
| Tamoxifen Citrate | 14 | $1,030 | $74 |
| Duloxetine | 22 | $1,012 | $46 |
| Hydrocodone-Acetaminophen | 26 | $963 | $37 |
| Prochlorperazine Maleate | 58 | $898 | $15 |
| Dexamethasone | 57 | $811 | $14 |
| Letrozole | 31 | $723 | $23 |
| Dapsone | 13 | $692 | $53 |
| Ondansetron | 28 | $522 | $19 |
| Levoxyl | 13 | $436 | $34 |
| Gabapentin | 39 | $422 | $11 |
| Levothyroxine | 20 | $319 | $16 |
| Fluconazole | 11 | $259 | $24 |
| Prednisone | 26 | $167 | $6 |
| Sulfamethoxazole-Trimethoprim | 38 | $158 | $4 |
| Furosemide | 14 | $53 | $4 |
2019: 43 drugs
| Revlimid | 78 | $1,084,384 | $13,902 |
| Imbruvica | 50 | $618,281 | $12,366 |
| Aranesp | 153 | $519,523 | $3,396 |
| Ibrance | 26 | $316,915 | $12,189 |
| Keytruda | 31 | $312,159 | $10,070 |
| Tagrisso | 19 | $300,884 | $15,836 |
| Jakafi | 11 | $210,002 | $19,091 |
| Xgeva | 88 | $207,516 | $2,358 |
| Promacta | 27 | $179,582 | $6,651 |
| Jadenu | 11 | $166,758 | $15,160 |
| Somatuline Depot | 20 | $164,673 | $8,234 |
| Nplate | 41 | $160,453 | $3,913 |
| Venclexta | 23 | $153,844 | $6,689 |
| Opdivo | 13 | $153,108 | $11,778 |
| Votrient | 11 | $124,951 | $11,359 |
| Tarceva | 12 | $108,579 | $9,048 |
| Abiraterone Acetate | 12 | $73,206 | $6,101 |
| Velcade | 16 | $64,558 | $4,035 |
| Imfinzi | 16 | $37,610 | $2,351 |
| Xarelto | 64 | $31,428 | $491 |
| Faslodex | 12 | $27,449 | $2,287 |
| Eliquis | 46 | $21,100 | $459 |
| Anastrozole | 108 | $3,625 | $34 |
| Hydroxyurea | 82 | $3,079 | $38 |
| Gemcitabine | 14 | $2,006 | $143 |
| Ondansetron | 40 | $1,094 | $27 |
| Dexamethasone | 62 | $1,056 | $17 |
| Carboplatin | 13 | $739 | $57 |
| Dapsone | 13 | $733 | $56 |
| Hydrocodone-Acetaminophen | 28 | $634 | $23 |
| Levothyroxine | 34 | $629 | $19 |
| Acyclovir | 32 | $596 | $19 |
| Letrozole | 20 | $557 | $28 |
| Diphenoxylate-Atropine | 14 | $529 | $38 |
| Warfarin | 18 | $364 | $20 |
| Prochlorperazine Maleate | 33 | $342 | $10 |
| Levofloxacin | 12 | $159 | $13 |
| Sulfamethoxazole-Trimethoprim | 29 | $152 | $5 |
| Furosemide | 23 | $116 | $5 |
| Gabapentin | 15 | $111 | $7 |
| Prednisone | 15 | $102 | $7 |
| Allopurinol | 14 | $84 | $6 |
| Lorazepam | 11 | $82 | $7 |
2018: 32 drugs
| Revlimid | 51 | $787,703 | $15,445 |
| Ibrance | 56 | $645,449 | $11,526 |
| Imbruvica | 37 | $390,908 | $10,565 |
| Tagrisso | 23 | $362,111 | $15,744 |
| Jakafi | 20 | $331,541 | $16,577 |
| Aranesp | 99 | $317,164 | $3,204 |
| Xgeva | 78 | $177,588 | $2,277 |
| Nplate | 23 | $137,653 | $5,985 |
| Promacta | 16 | $86,241 | $5,390 |
| Faslodex | 18 | $38,673 | $2,148 |
| Creon | 16 | $26,864 | $1,679 |
| Xarelto | 60 | $25,257 | $421 |
| Eliquis | 45 | $19,102 | $424 |
| Anastrozole | 126 | $3,105 | $25 |
| Hydroxyurea | 69 | $2,294 | $33 |
| Doxycycline Hyclate | 17 | $839 | $49 |
| Dexamethasone | 33 | $737 | $22 |
| Tamoxifen Citrate | 22 | $692 | $31 |
| Oxycodone | 14 | $671 | $48 |
| Letrozole | 31 | $607 | $20 |
| Morphine Sulfate Er | 15 | $508 | $34 |
| Hydrocodone-Acetaminophen | 23 | $428 | $19 |
| Ondansetron | 25 | $287 | $11 |
| Triamcinolone Acetonide | 22 | $276 | $13 |
| Prochlorperazine Maleate | 22 | $189 | $9 |
| Pantoprazole | 15 | $156 | $10 |
| Acyclovir | 11 | $110 | $10 |
| Lorazepam | 19 | $101 | $5 |
| Prednisone | 15 | $86 | $6 |
| Sulfamethoxazole-Trimethoprim | 14 | $79 | $6 |
| Amlodipine Besylate | 33 | $78 | $2 |
| Furosemide | 11 | $52 | $5 |
2017: 36 drugs
| Revlimid | 64 | $746,961 | $11,671 |
| Jakafi | 20 | $304,761 | $15,238 |
| Aranesp | 93 | $270,180 | $2,905 |
| Ibrance | 21 | $231,792 | $11,038 |
| Imbruvica | 28 | $204,009 | $7,286 |
| Neulasta | 32 | $189,073 | $5,909 |
| Nexavar | 13 | $188,639 | $14,511 |
| Pomalyst | 11 | $165,716 | $15,065 |
| Gilotrif | 13 | $103,836 | $7,987 |
| Xgeva | 36 | $78,445 | $2,179 |
| Promacta | 12 | $47,392 | $3,949 |
| Xarelto | 60 | $22,972 | $383 |
| Creon | 18 | $13,183 | $732 |
| Eliquis | 30 | $11,772 | $392 |
| Hydroxyurea | 65 | $2,331 | $36 |
| Anastrozole | 96 | $2,274 | $24 |
| Megestrol Acetate | 16 | $957 | $60 |
| Ondansetron | 42 | $727 | $17 |
| Tamoxifen Citrate | 34 | $727 | $21 |
| Oxycodone | 18 | $669 | $37 |
| Letrozole | 33 | $639 | $19 |
| Dexamethasone | 56 | $494 | $9 |
| Hydrocodone-Acetaminophen | 28 | $362 | $13 |
| Valacyclovir | 11 | $329 | $30 |
| Warfarin | 14 | $318 | $23 |
| Prochlorperazine Maleate | 32 | $250 | $8 |
| Acyclovir | 23 | $246 | $11 |
| Duloxetine | 13 | $228 | $18 |
| Lorazepam | 21 | $190 | $9 |
| Pantoprazole | 20 | $164 | $8 |
| Prednisone | 26 | $127 | $5 |
| Sulfamethoxazole-Trimethoprim | 19 | $95 | $5 |
| Famotidine | 14 | $92 | $7 |
| Citalopram Hbr | 13 | $81 | $6 |
| Amlodipine Besylate | 18 | $56 | $3 |
| Furosemide | 12 | $29 | $2 |
2016: 26 drugs
| Revlimid | 39 | $305,891 | $7,843 |
| Jakafi | 22 | $297,372 | $13,517 |
| Imbruvica | 38 | $296,969 | $7,815 |
| Ibrance | 22 | $227,112 | $10,323 |
| Nexavar | 11 | $154,277 | $14,025 |
| Stivarga | 11 | $152,889 | $13,899 |
| Aranesp | 46 | $106,539 | $2,316 |
| Xtandi | 11 | $93,872 | $8,534 |
| Xgeva | 29 | $59,314 | $2,045 |
| Xarelto | 54 | $19,024 | $352 |
| Anastrozole | 66 | $1,947 | $30 |
| Hydroxyurea | 58 | $1,509 | $26 |
| Hydrocodone-Acetaminophen | 21 | $756 | $36 |
| Letrozole | 20 | $684 | $34 |
| Tamoxifen Citrate | 29 | $524 | $18 |
| Ondansetron | 26 | $448 | $17 |
| Oxycodone | 18 | $391 | $22 |
| Dexamethasone | 45 | $372 | $8 |
| Duloxetine | 12 | $294 | $25 |
| Pantoprazole | 32 | $226 | $7 |
| Prochlorperazine Maleate | 27 | $203 | $8 |
| Warfarin | 13 | $196 | $15 |
| Lorazepam | 17 | $145 | $9 |
| Amlodipine Besylate | 21 | $112 | $5 |
| Furosemide | 22 | $59 | $3 |
| Prednisone | 12 | $51 | $4 |
2015: 28 drugs
| Revlimid | 28 | $228,935 | $8,176 |
| Jakafi | 19 | $226,742 | $11,934 |
| Imbruvica | 28 | $199,662 | $7,131 |
| Zytiga | 11 | $85,914 | $7,810 |
| Xgeva | 15 | $28,174 | $1,878 |
| Aranesp | 12 | $28,050 | $2,338 |
| Xarelto | 29 | $9,553 | $329 |
| Anastrozole | 50 | $1,233 | $25 |
| Hydrocodone-Acetaminophen | 27 | $1,201 | $44 |
| Hydroxyurea | 19 | $883 | $46 |
| Tamoxifen Citrate | 21 | $562 | $27 |
| Morphine Sulfate Er | 11 | $540 | $49 |
| Ondansetron | 21 | $516 | $25 |
| Megestrol Acetate | 12 | $505 | $42 |
| Potassium Chloride | 17 | $460 | $27 |
| Oxycodone | 16 | $352 | $22 |
| Dexamethasone | 45 | $309 | $7 |
| Prednisone | 35 | $282 | $8 |
| Prochlorperazine Maleate | 33 | $230 | $7 |
| Pantoprazole | 22 | $218 | $10 |
| Warfarin | 16 | $167 | $10 |
| Acyclovir | 13 | $148 | $11 |
| Amlodipine Besylate | 16 | $99 | $6 |
| Omeprazole | 11 | $93 | $8 |
| Sulfamethoxazole-Trimethoprim | 17 | $68 | $4 |
| Citalopram Hbr | 14 | $64 | $5 |
| Trazodone | 14 | $57 | $4 |
| Furosemide | 14 | $37 | $3 |
2014: 21 drugs
| Revlimid | 25 | $238,980 | $9,559 |
| Imbruvica | 19 | $160,999 | $8,474 |
| Xgeva | 20 | $35,498 | $1,775 |
| Oxycontin | 15 | $8,875 | $592 |
| Xarelto | 15 | $5,434 | $362 |
| Dronabinol | 12 | $4,553 | $379 |
| Anastrozole | 45 | $1,539 | $34 |
| Hydrocodone-Acetaminophen | 52 | $1,320 | $25 |
| Morphine Sulfate Er | 16 | $1,303 | $81 |
| Hydroxyurea | 20 | $971 | $49 |
| Ondansetron | 35 | $713 | $20 |
| Oxycodone | 31 | $630 | $20 |
| Temazepam | 15 | $404 | $27 |
| Acyclovir | 19 | $331 | $17 |
| Dexamethasone | 35 | $312 | $9 |
| Prednisone | 29 | $296 | $10 |
| Prochlorperazine Maleate | 25 | $157 | $6 |
| Pantoprazole | 16 | $123 | $8 |
| Warfarin | 12 | $120 | $10 |
| Lorazepam | 19 | $99 | $5 |
| Ciprofloxacin | 11 | $47 | $4 |
2013: 14 drugs
| Revlimid | 34 | $307,026 | $9,030 |
| Xarelto | 28 | $8,149 | $291 |
| Ondansetron | 31 | $832 | $27 |
| Hydrocodone-Acetaminophen | 39 | $730 | $19 |
| Anastrozole | 17 | $521 | $31 |
| Megestrol Acetate | 12 | $515 | $43 |
| Acyclovir | 18 | $393 | $22 |
| Warfarin | 33 | $361 | $11 |
| Dexamethasone | 39 | $273 | $7 |
| Prochlorperazine Maleate | 37 | $242 | $7 |
| Lorazepam | 32 | $171 | $5 |
| Citalopram Hbr | 15 | $103 | $7 |
| Prednisone | 22 | $81 | $4 |
| Zolpidem | 11 | $41 | $4 |
Money from drug and device companies
$1,450 in 2025
| 2025 | 31 | 53 | None | $1,450 |
| 2024 | 27 | 60 | $765 | $2,341 |
| 2023 | 29 | 59 | $1,320 | $2,824 |
| 2022 | 24 | 51 | None | $1,584 |
| 2021 | 30 | 61 | $3,850 | $4,984 |
| 2020 | 21 | 35 | $2,615 | $3,300 |
| 2019 | 31 | 90 | $21,500 | $26,414 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Celgene | Reblozyl | $173 | 8 payments
|
| Pfizer | Ibrance | $155 | 6 payments
|
| Abbvie | Imbruvica | $75 | 3 payments
|
| Taiho Oncology | Lonsurf | $71 | 2 payments
|
| Exelixis | Cabometyx | $68 | 2 payments
|
| Janssen Biotech | Rybrevant | $65 | 2 payments
|
See all 53 published payments
| Celgene | Meals · 2025-12-11 | Reblozyl | $10 |
| Celgene | Meals · 2025-12-04 | Reblozyl | $25 |
| Adc Therapeutics America | Meals · 2025-10-27 | Zynlonta | $35 |
| Pfizer | Meals · 2025-10-20 | Padcev | $34 |
| Abbvie | Meals · 2025-10-14 | Imbruvica | $19 |
| Genentech USA | Meals · 2025-10-06 | Polivy | $32 |
| Celgene | Meals · 2025-10-03 | Reblozyl | $26 |
| Rigel Pharmaceuticals | Meals · 2025-09-29 | Tavalisse | $16 |
| Octapharma USA | Meals · 2025-09-22 | Octagam Immune Globulin (Human) | $38 |
| Genentech USA | Meals · 2025-09-19 | Phesgo | $28 |
| GlaxoSmithKline | Meals · 2025-09-15 | Ojjaara | $25 |
| Exelixis | Meals · 2025-09-15 | Cabometyx | $40 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-09-12 | Imfinzi | $32 |
| Exelixis | Meals · 2025-08-26 | Cabometyx | $29 |
| Syndax Pharmaceuticals | Meals · 2025-08-14 | Revuforj | $27 |
| Ipsen Biopharmaceuticals | Meals · 2025-07-28 | Onivyde | $32 |
| Lilly USA | Meals · 2025-07-07 | Jaypirca | $33 |
| Regeneron Healthcare Solutions | Meals · 2025-06-30 | Libtayo | $36 |
| GlaxoSmithKline | Meals · 2025-06-23 | Jemperli | $26 |
| Janssen Biotech | Meals · 2025-06-09 | Tecvayli | $23 |
| Genmab U.S. | Meals · 2025-06-06 | Epkinly | $27 |
| Eisai | Meals · 2025-05-30 | Lenvima | $31 |
| Pfizer | Meals · 2025-05-27 | Xtandi | $29 |
| Janssen Biotech | Meals · 2025-05-22 | Rybrevant | $42 |
| Taiho Oncology | Meals · 2025-05-19 | Lonsurf | $31 |
| Deciphera Pharmaceuticals | Meals · 2025-05-09 | Qinlock | $30 |
| SpringWorks Therapeutics | Meals · 2025-05-05 | Ogsiveo | $41 |
| Celgene | Meals · 2025-04-29 | Reblozyl | $13 |
| Incyte | Meals · 2025-04-25 | Monjuvi | $26 |
| Alexion Pharmaceuticals | Meals · 2025-04-21 | Ultomiris | $18 |
| Pfizer | Meals · 2025-04-18 | Ibrance | $35 |
| Pfizer | Meals · 2025-04-18 | Ibrance | $3 |
| Gilead Sciences | Meals · 2025-04-15 | Trodelvy | $16 |
| Gilead Sciences | Meals · 2025-04-14 | Trodelvy | $23 |
| BeOne Medicines USA | Meals · 2025-04-09 | Brukinsa | $27 |
| Celgene | Meals · 2025-03-31 | Reblozyl | $26 |
| Celgene | Meals · 2025-03-24 | Opdivo | $34 |
| Abbvie | Meals · 2025-03-22 | Imbruvica | $27 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-03-14 | Enhertu | $31 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-03-14 | Stivarga | $23 |
| Pfizer | Meals · 2025-03-07 | Eliquis | $23 |
| Celgene | Meals · 2025-03-05 | Reblozyl | $26 |
| Daiichi Sankyo | Meals · 2025-03-03 | Vanflyta | $27 |
| Taiho Oncology | Meals · 2025-02-27 | Lonsurf | $41 |
| Legend Biotech USA | Meals · 2025-02-18 | Carvykti | $28 |
| Agios Pharmaceuticals | Meals · 2025-02-10 | Pyrukynd | $23 |
| Pfizer | Meals · 2025-02-07 | Bosulif | $31 |
| Abbvie | Meals · 2025-02-04 | Creon | $29 |
| Sobi | Meals · 2025-01-31 | Vonjo | $25 |
| Geron | Meals · 2025-01-27 | Rytelo | $36 |
| Adc Therapeutics America | Meals · 2025-01-21 | Zynlonta | $15 |
| Stemline Therapeutics | Meals · 2025-01-14 | Orserdu | $35 |
| Celgene | Meals · 2025-01-08 | Reblozyl | $12 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $2,341
| E.R. Squibb & Sons L.L.C. | Opdivo | $835 | 6 payments
|
| Incyte | Monjuvi | $201 | 4 payments
|
| Gilead Sciences | Trodelvy | $180 | 5 payments
|
| Abbvie | Imbruvica | $143 | 7 payments
|
| Pfizer | Ibrance | $114 | 4 payments
|
| Exelixis | Cabometyx | $83 | 2 payments
|
| Celgene | Reblozyl | $77 | 4 payments
|
| Novartis Pharmaceuticals | Fabhalta | $63 | 3 payments
|
| Takeda Pharmaceuticals U.S.A. | Alunbrig | $61 | 2 payments
|
| AstraZeneca Pharmaceuticals LP | Imfinzi | $57 | 2 payments
|
| Alexion Pharmaceuticals | Ultomiris | $53 | 2 payments
|
| Genzyme | Sarclisa | $52 | 2 payments
|
| Merck Sharp & Dohme | Keytruda | $51 | 2 payments
|
| Ipsen Biopharmaceuticals | Onivyde | $49 | 1 payment
|
| Janssen Biotech | Tecvayli | $43 | 2 payments
|
| Sobi | Vonjo | $35 | 1 payment
|
| Coherus Biosciences | Loqtorzi | $34 | 1 payment
|
| Lilly USA | Jaypirca | $26 | 1 payment
|
| GlaxoSmithKline | Ojjaara | $25 | 1 payment
|
| Eisai | Lenvima | $25 | 1 payment
|
| Mirati Therapeutics | Krazati | $23 | 1 payment
|
| Apellis Pharmaceuticals | Empaveli | $22 | 1 payment
|
| Daiichi Sankyo | Enhertu | $20 | 1 payment
|
| Secura Bio | Copiktra | $20 | 1 payment
|
| Astellas Pharma US | Xospata | $20 | 1 payment
|
| Pharmacosmos Therapeutics | Cosela | $17 | 1 payment
|
| Regeneron Healthcare Solutions | Libtayo | $13 | 1 payment
|
2023: $2,824
| Servier Pharmaceuticals | Tibsovo | $1,340 | 2 payments
|
| Seagen | Adcetris | $143 | 3 payments
|
| E.R. Squibb & Sons L.L.C. | Opdivo | $131 | 8 payments
|
| Takeda Pharmaceuticals U.S.A. | Alunbrig | $115 | 2 payments
|
| Pharmacyclics LLC An AbbVie | Epkinly | $84 | 4 payments
|
| Exelixis | Cabometyx | $77 | 2 payments
|
| AstraZeneca Pharmaceuticals LP | Tagrisso | $76 | 3 payments
|
| Merck Sharp & Dohme | Keytruda | $73 | 3 payments
|
| ADC Therapeutics America | None | $73 | 3 payments
|
| Pfizer | Ibrance | $72 | 4 payments
|
| Janssen Biotech | Rybrevant | $63 | 2 payments
|
| Celgene | Pomalyst | $61 | 3 payments
|
| PharmaEssentia USA | Besremi | $57 | 2 payments
|
| Amgen | Nplate | $55 | 2 payments
|
| Astellas Pharma US | Xospata | $52 | 2 payments
|
| Genentech USA | Lunsumio | $31 | 1 payment
|
| Blueprint Medicines | Ayvakit | $30 | 1 payment
|
| Karyopharm Therapeutics | Xpovio | $30 | 1 payment
|
| Bayer Healthcare Pharmaceuticals | Nubeqa | $28 | 1 payment
|
| Lilly USA | Verzenio | $28 | 1 payment
|
| AbbVie | Creon | $28 | 1 payment
|
| GlaxoSmithKline | Zejula | $27 | 1 payment
|
| Novartis Pharmaceuticals | Scemblix | $26 | 1 payment
|
| Sobi | Doptelet | $26 | 1 payment
|
| Taiho Oncology | Lonsurf | $23 | 1 payment
|
| Eisai | Lenvima | $20 | 1 payment
|
| Alexion Pharmaceuticals | Ultomiris | $19 | 1 payment
|
| Secura Bio | Copiktra | $18 | 1 payment
|
| Myriad Genetic Laboratories | Precisetumor | $16 | 1 payment
|
2022: $1,584
| Epizyme | Tazverik | $365 | 1 payment
|
| Seagen | Adcetris | $231 | 6 payments
|
| E.R. Squibb & Sons L.L.C. | Opdivo | $103 | 5 payments
|
| Lilly USA | Verzenio | $84 | 3 payments
|
| Novartis Pharmaceuticals | Promacta | $71 | 3 payments
|
| Pfizer | Ibrance | $68 | 3 payments
|
| Pharmacyclics LLC an AbbVie | Imbruvica | $66 | 3 payments
|
| GlaxoSmithKline | Zejula | $65 | 2 payments
|
| Janssen Biotech | Erleada | $63 | 3 payments
|
| Servier Pharmaceuticals | Oncaspar | $58 | 3 payments
|
| Merck Sharp & Dohme | Keytruda | $48 | 2 payments
|
| Celgene | Reblozyl | $45 | 2 payments
|
| Gilead Sciences | Trodelvy | $44 | 2 payments
|
| Astellas Pharma US | Xtandi | $43 | 2 payments
|
| Acrotech Biopharma | Beleodaq | $32 | 2 payments
|
| Exelixis | Cabometyx | $31 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Enhertu | $25 | 1 payment
|
| Amgen | Lumakras | $24 | 1 payment
|
| Abbvie | Creon | $23 | 1 payment
|
| Rigel Pharmaceuticals | Tavalisse | $22 | 1 payment
|
| ADC Therapeutics America | None | $21 | 1 payment
|
| Daiichi Sankyo | Enhertu | $21 | 1 payment
|
| Sobi | Doptelet | $18 | 1 payment
|
| BeiGene USA | Brukinsa | $14 | 1 payment
|
2021: $4,984
| Seagen | Adcetris | $2,287 | 6 payments
|
| AbbVie | Venclexta | $1,672 | 2 payments
|
| Pharmacyclics LLC An AbbVie | Imbruvica | $170 | 10 payments
|
| Pfizer | Ibrance | $124 | 7 payments
|
| Janssen Biotech | Erleada | $67 | 3 payments
|
| Exelixis | Cabometyx | $58 | 2 payments
|
| Alexion Pharmaceuticals | Ultomiris | $44 | 2 payments
|
| GlaxoSmithKline | Blenrep | $44 | 2 payments
|
| Pharmacosmos Therapeutics | Monoferric | $41 | 3 payments
|
| Coherus Biosciences | Udenyca | $39 | 1 payment
|
| Servier Pharmaceuticals | Oncaspar | $39 | 2 payments
|
| Incyte | Jakafi | $35 | 2 payments
|
| Novartis Pharmaceuticals | Kisqali | $31 | 2 payments
|
| Amgen | Lumakras | $26 | 1 payment
|
| Taiho Oncology | Lonsurf | $24 | 1 payment
|
| Kite Pharma | None | $23 | 1 payment
|
| Boehringer Ingelheim Pharmaceuticals | Cosela | $22 | 1 payment
|
| EMD Serono | None | $22 | 1 payment
|
| Merck Sharp & Dohme | Keytruda | $21 | 1 payment
|
| Genzyme | Libtayo | $21 | 1 payment
|
| Clovis Oncology | Rubraca | $20 | 1 payment
|
| Eisai | Lenvima | $20 | 1 payment
|
| Jazz Pharmaceuticals | Zepzelca | $20 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | Opdivo | $18 | 1 payment
|
| Epizyme | Tazverik | $18 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Tagrisso | $17 | 1 payment
|
| Takeda Pharmaceuticals U.S.A. | Ninlaro | $17 | 1 payment
|
| Astellas Pharma US | Xtandi | $17 | 1 payment
|
| Celgene | Abecma | $14 | 1 payment
|
| Gilead Sciences | None | $12 | 1 payment
|
2020: $3,300
| Celgene | None | $1,695 | 1 payment
|
| Seagen | Adcetris | $943 | 2 payments
|
| Exelixis | Cabometyx | $101 | 4 payments
|
| E.R. Squibb & Sons L.L.C. | Opdivo | $58 | 3 payments
|
| Pharmacyclics LLC An AbbVie | Imbruvica | $53 | 2 payments
|
| Janssen Biotech | Imbruvica | $43 | 3 payments
|
| Pfizer | Ibrance | $42 | 3 payments
|
| Takeda Pharmaceuticals U.S.A. | Alunbrig | $41 | 2 payments
|
| Daiichi Sankyo | Enhertu | $40 | 2 payments
|
| GlaxoSmithKline | Blenrep | $32 | 1 payment
|
| Rigel Pharmaceuticals | Tavalisse | $30 | 2 payments
|
| Karyopharm Therapeutics | Xpovio | $30 | 1 payment
|
| Astellas Pharma US | Padcev | $25 | 1 payment
|
| Genzyme | Jevtana | $24 | 1 payment
|
| Jazz Pharmaceuticals | Vyxeos | $24 | 1 payment
|
| Allergan | Zenpep | $23 | 1 payment
|
| EMD Serono | Bavencio | $21 | 1 payment
|
| Merck Sharp & Dohme | Keytruda | $20 | 1 payment
|
| Amgen | Neulasta | $20 | 1 payment
|
| Incyte | Jakafi | $20 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Tagrisso | $17 | 1 payment
|
2019: $26,414
| Seattle Genetics | Adcetris | $24,978 | 24 payments
|
| Alexion Pharmaceuticals | Soliris | $136 | 3 payments
|
| Sirtex Medical | Sir-Spheres Microspheres | $120 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | Eliquis | $100 | 5 payments
|
| Amgen | Kyprolis | $99 | 5 payments
|
| Exelixis | Cabometyx | $89 | 4 payments
|
| Novartis Pharmaceuticals | Tasigna | $76 | 4 payments
|
| Astellas Pharma US | Xtandi | $62 | 4 payments
|
| Pfizer | Ibrance | $59 | 4 payments
|
| Genzyme | Cerezyme | $57 | 3 payments
|
| Merck Sharp & Dohme | Keytruda | $55 | 3 payments
|
| Janssen Biotech | Balversa | $54 | 3 payments
|
| Pharmacyclics LLC An AbbVie | Imbruvica | $47 | 2 payments
|
| Puma Biotechnology | Nerlynx | $46 | 2 payments
|
| Rigel Pharmaceuticals | Tavalisse | $42 | 2 payments
|
| Takeda Pharmaceuticals U.S.A. | Ninlaro | $41 | 2 payments
|
| Celgene | Abraxane | $40 | 2 payments
|
| Clovis Oncology | Rubraca | $38 | 3 payments
|
| Incyte | Jakafi | $34 | 2 payments
|
| Bayer HealthCare Pharmaceuticals | Nubeqa | $25 | 1 payment
|
| AbbVie | Venclexta | $24 | 1 payment
|
| Lilly USA | Erbitux | $23 | 1 payment
|
| Servier Pharmaceuticals | Oncaspar | $22 | 1 payment
|
| Eisai | Halaven | $22 | 1 payment
|
| Agios Pharmaceuticals | Tibsovo | $21 | 1 payment
|
| Genentech USA | Gazyva | $21 | 1 payment
|
| Janssen Pharmaceuticals | Xarelto | $19 | 1 payment
|
| Tesaro | Zejula | $17 | 1 payment
|
| Verastem | Copiktra | $17 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Lynparza | $16 | 1 payment
|
| Spectrum Pharmaceuticals | Folotyn | $16 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 100.0 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1518155357
- Licence
- CA A82830California A82830: Current · expires 2028-08-31
- Trained
- University of Washington School of Medicine, 2001 · 25 years ago
- Group
- Sutter Bay Medical Foundation · Pacific Hematology Oncology Assoc.
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RH0003X (207RH0003X)
- Mailing address
- 2100 Webster St Ste 225, San Francisco, CA, 94115
- NPI first listed
- 2007-10-05
- NPI last updated
- 2013-02-28
This is when the NPI record was last certified, not a medical board exam.